Cell and gene therapies promise transformative outcomes for patients, yet realizing that promise requires navigating immense operational, regulatory, and ecosystem complexity.
In this two-part discussion, Beghou Partner Vishal Singal and ARM COO Rita Johnson-Greene explore what’s driving progress in cell and gene therapy (CGT), what continues to hold the field back, and what needs to evolve for long-term success. Together, they share lessons from across the industry, emphasizing the importance of education, collaboration, and forward-thinking models to build a sustainable and equitable future for CGT.
Key topics
Podcast 1: Defining Success in Today’s CGT Landscape
-
What’s working and what’s not: Why it’s critical to first level set success to understand where the CGT ecosystem is thriving and where it continues to face barriers.
-
Building the patient ecosystem: How each stakeholder, from manufacturers to regulators, must be educated differently to create alignment and improve collaboration.
-
Expanding opportunity: Exploring the immense potential that continues to emerge across the CGT landscape.
Podcast 2: The Path Forward — Operating Models and the Future of CGT
-
Evolving the operating model: How to strengthen engagement with regulatory agencies and governing bodies, including education around international frameworks such as Japanese subsidies.
-
Educating and expanding patient populations: How to improve awareness, outreach, and re-engagement strategies to bring more patients into the treatment ecosystem.
-
Innovating payment models: Exploring subscription and other alternative payment approaches to advance health equity and access.
-
Scaling treatment centers: How to extend beyond specialized hubs into community centers while expanding the trained physician base.
-
Advancing manufacturing: How emerging technologies can accelerate production and improve efficiency across the CGT value chain